Young male patients with atrial fibrillation and CHA2DS2-VASc score of 1 may not need anticoagulants: A nationwide population-based study

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Chan, Yi Hsin ^a,b   Wu, Lung Sheng ^a,b   Chang, Shang Hung ^a,b   Lee, Hsin Fu ^a,b   Liu, Jia Rou ^b   See, Lai Chu ^a,b,c   Yeh, Yung Hsin ^a,b   Kuo, Chi Tai ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGE; AGED; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE ASSESSMENT; CHA2DS2 VASC SCORE; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT RISK; POPULATION RESEARCH; RISK FACTOR; SEX DIFFERENCE; THROMBOEMBOLISM; COMPLICATION; RISK ASSESSMENT; TAIWAN; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; TAIWAN; THROMBOEMBOLISM; YOUNG ADULT;

EID: 84977496601     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151485     Document Type: Article

References (32)

1. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996; 27(10):1760-4. PMID: 8841325.
2. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137(2):263-72. doi: 10.1378/chest.09-1584 PMID: 19762550.
3. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011; 342:d124. doi: 10.1136/bmj.d124 PMID: 21282258; PubMed Central PMCID: PMC3031123.
4. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost. 2012; 107(6):1172-9. doi: 10.1160/TH12-03-0175 PMID: 22473219.
5. Chao TF, Lin YJ, Tsao HM, Tsai CF, Lin WS, Chang SL, et al. CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation. J Am Coll Cardiol. 2011; 58(23):2380-5. doi: 10.1016/j.jacc.2011.08.045 PMID: 22115643.
6. Chao TF, Liu CJ, Chen SJ, Wang KL, Lin YJ, Chang SL, et al. Atrial fibrillation and the risk of ischemic stroke: does it still matter in patients with a CHA2DS2-VASc score of 0 or 1? Stroke. 2012; 43 (10):2551-5. doi: 10.1161/STROKEAHA.112.667865 PMID: 22871677.
7. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012; 33(21):2719-47. doi: 10.1093/eurheartj/ehs253 PMID: 22922413.
8. Jung BC, Kim NH, Nam GB, Park HW, On YK, Lee YS, et al. The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society. Korean Circ J. 2015; 45(1):9-19. doi: 10.4070/kcj.2015.45.1.9 PMID: 25653698; PubMed Central PMCID: PMC4310986.
9. Jones C, Pollit V, Fitzmaurice D, Cowan C, Guideline Development G. The management of atrial fibrillation: summary of updated NICE guidance. BMJ. 2014; 348:g3655. doi: 10.1136/bmj.g3655 PMID: 24948694.
10. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014; 130(23):2071-104. doi: 10.1161/CIR.0000000000000040 PMID: 24682348.
11. Lin LJ, Cheng MH, Lee CH, Wung DC, Cheng CL, Kao Yang YH. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation-a nationwide descriptive study in Taiwan. Clin Ther. 2008; 30(9):1726-36. doi: 10.1016/j.clinthera.2008.09.010 PMID: 18840379.
12. Chang CH, Lee YC, Tsai CT, Chang SN, Chung YH, Lin MS, et al. Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease. Atherosclerosis. 2014; 232(1):224-30. doi: 10.1016/j.atherosclerosis.2013.11.036 PMID: 24401243.
13. Maaijwee NA, Rutten-Jacobs LC, Schaapsmeerders P, van Dijk EJ, de Leeuw FE. Ischaemic stroke in young adults: risk factors and long-term consequences. Nat Rev Neurol. 2014; 10(6):315-25. doi: 10.1038/nrneurol.2014.72 PMID: 24776923.
14. Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc. 2005; 104(3):157-63. PMID: 15818428.
15. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011; 20(3):236-42. doi: 10.1002/pds.2087 PMID: 21351304.
16. Hsieh CY, Chen CH, Li CY, Lai ML. Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. J Formos Med Assoc. 2015; 114(3):254-9. doi: 10.1016/j.jfma. 2013.09.009 PMID: 24140108.
17. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139-51. doi: 10.1056/NEJMoa0905561 PMID: 19717844.
18. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-91. doi: 10.1056/NEJMoa1009638 PMID: 21830957.
19. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-92. doi: 10.1056/NEJMoa1107039 PMID: 21870978.
20. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22):2093-104. doi: 10.1056/NEJMoa1310907 PMID: 24251359.
21. Lip GY, Wang KL, Chiang CE. Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal. Int J Cardiol. 2015; 180:246-54. doi: 10.1016/j.ijcard.2014.11.182 PMID: 25463377.
22. Wolf PA, D'Agostino RB, O'Neal MA, Sytkowski P, Kase CS, Belanger AJ, et al. Secular trends in stroke incidence and mortality. The Framingham Study. Stroke. 1992; 23(11):1551-5. PMID: 1440701.
23. Higashi Y, Kihara Y, Noma K. Endothelial dysfunction and hypertension in aging. Hypertens Res. 2012; 35(11):1039-47. doi: 10.1038/hr.2012.138 PMID: 22972557.
24. Sohrabji F, Bake S, Lewis DK. Age-related changes in brain support cells: Implications for stroke severity. Neurochem Int. 2013; 63(4):291-301. doi: 10.1016/j.neuint.2013.06.013 PMID: 23811611; PubMed Central PMCID: PMC3955169.
25. Mayhan WG, Arrick DM, Sharpe GM, Sun H. Age-related alterations in reactivity of cerebral arterioles: role of oxidative stress. Microcirculation. 2008; 15(3):225-36. doi: 10.1080/10739680701641421 PMID: 18386218.
26. Park L, Anrather J, Girouard H, Zhou P, Iadecola C. Nox2-derived reactive oxygen species mediate neurovascular dysregulation in the aging mouse brain. J Cereb Blood Flow Metab. 2007; 27(12):1908-18. doi: 10.1038/sj.jcbfm.9600491 PMID: 17429347.
27. Modrick ML, Didion SP, Sigmund CD, Faraci FM. Role of oxidative stress and AT1 receptors in cerebral vascular dysfunction with aging. Am J Physiol Heart Circ Physiol. 2009; 296(6):H1914-9. doi: 10.1152/ajpheart.00300.2009 PMID: 19395552; PubMed Central PMCID: PMC2716103.
28. Pena Silva RA, Chu Y, Miller JD, Mitchell IJ, Penninger JM, Faraci FM, et al. Impact of ACE2 deficiency and oxidative stress on cerebrovascular function with aging. Stroke. 2012; 43(12):3358-63. doi: 10.1161/STROKEAHA.112.667063 PMID: 23160880; PubMed Central PMCID: PMC3529166.
29. Blum A, Vaispapir V, Keinan-Boker L, Soboh S, Yehuda H, Tamir S. Endothelial dysfunction and procoagulant activity in acute ischemic stroke. J Vasc Interv Neurol. 2012; 5(1):33-9. PMID: 22737264; PubMed Central PMCID: PMC3379907.
30. Stroke Risk in Atrial Fibrillation Working G. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007; 69(6):546-54. doi: 10.1212/01.wnl.0000267275.68538. 8d PMID: 17679673.
31. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285(22):2864-70. PMID: 11401607.
32. Stroke Risk in Atrial Fibrillation Working G. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008; 39(6):1901-10. doi: 10.1161/STROKEAHA.107.501825 PMID: 18420954.